Moment Of Truth For Daiichi/AstraZeneca’s Enhertu In EU

 
• By Neena Brizmohun

The EU marketing application for the HER2-targeted antibody drug conjugate has been fast-tracked and is now up for an opinion from the European Medicines Agency.

Concept of national healthcare system - EU - European Union
EU regulators are deciding whether trastuzumab deruxtecan should be approved • Source: Shutterstock

More from Product Reviews

More from Pink Sheet